The FDA has approved Merck’s Keytruda in combination with chemotherapy for the first-line treatment of malignant pleural mesothelioma (MPM). This approval marks the first indication for Keytruda in MPM in the U.S. and is based on clinical trial data showing significant improvements in overall survival and progression-free survival compared to chemotherapy alone.